



UNITED STATES PATENT AND TRADEMARK OFFICE

141
CIVI²
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/395,409	09/14/1999	CHARLES CANTOR	25491-2403D	6005

24961 7590 01/22/2002
HELLER EHRLMAN WHITE & MCAULIFFE LLP
4250 EXECUTIVE SQ
7TH FLOOR
LA JOLLA, CA 92037

EXAMINER	
CHAKRABARTI, ARUN K	
ART UNIT	PAPER NUMBER
1655	

DATE MAILED: 01/22/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/395,409	Applicant(s) Cantor
Examiner Arun Chakrabarti	Art Unit 1655



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM

THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Jan 4, 2002

2a) This action is FINAL.

2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-55, 58-60, 63-77, 86, and 88-128 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-55, 58-60, 63-77, 86, and 88-128 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are objected to by the Examiner.

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

15) Notice of References Cited (PTO-892)

18) Interview Summary (PTO-413) Paper No(s). _____

16) Notice of Draftsperson's Patent Drawing Review (PTO-948)

19) Notice of Informal Patent Application (PTO-152)

17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 6 and 8

20) Other: _____

Art Unit:

DETAILED ACTION

Specification

1. Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claims 71-72 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 71 recites the limitation "the selectively releasable" in line 1 of the claim. There is insufficient antecedent basis for this limitation in the claim.

Regarding claim 71, the phrase "releasable" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention.

Art Unit:

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

5. Claims 1-27, 29-55, 58-60, 63-70, 73-77, 86, and 88-128 are rejected under 35 U.S.C. 102 (e) as being anticipated by Koster (U.S. Patent 5,605,798) (February 25, 1997).

Koster teaches a method for sequencing a target nucleic acid (Abstract), comprising the steps of:

- a) providing a set of nucleic acid fragments each containing a sequence that corresponds to a sequence of the target nucleic acid (Example 1 and Claim 1);
- b) hybridizing the set to an array of nucleic acid probes to form a target array of nucleic acids, wherein each probe comprises a single-stranded portion comprising a variable region (Example 1 and Claim 1 and Figure 1 and Column 4, lines 11-14 and Column 9, lines 28-43 and Figures 2-3); and
- c) determining molecular weights for nucleic acids of the target array by mass spectrometry (Example 1 and Claim 1 and Figures 1-11);

Art Unit:

whereby the sequence of the target nucleic acid is determined (Example 1 and Claim 1 and Figures 1-11).

Koster also teaches a method, wherein the molecular weights are determined by gel electrophoresis (Column 1, lines 61-66).

Koster also teaches a method, wherein the mass spectrometry comprises matrix-assisted laser desorption/ionization and electrospray (Examples 1-2).

Koster also teaches a method, wherein the mass spectrometry comprises time of flight analysis (Example 1 and Figures 9-10).

Koster also teaches a method, wherein two or more molecular weights are determined simultaneously (Example 2).

Koster teaches a method, further comprising the step of enzymatically extending the nucleic acid probes of the target array using the hybridized target nucleic acid as a template to form extended strands of DNA and RNA (Claims 9, 16, 20, and 43).

Koster teaches a method, wherein the step of extending is performed in the presence of chain elongating nucleotides and chain terminating nucleotides (Column 9, lines 54-67).

Koster teaches a method, wherein the array comprises nucleic acid probes having at least one mass-modifying functionality coupled to heterocyclic base, a sugar moiety or a phosphate group that does not interfere with hydrogen bonding for base-pair formation (Column 9, line 28 to Column 10, line 54 and Figure 6 and Claim 25).

Art Unit:

Koster teaches a method, wherein the mass-modifying functionality is coupled to a purine and deazapurine at position N7 and to apyrimidine at position C5 or C6 (Column 9, line 8 to column 10, line 35).

Koster teaches a method, wherein the mass-modifying functionality is selected from F, Cl, Br, CF₃, CH₂F, and CHF₂ and Si (C₂H₅)₃ (Column 10, lines 16-35).

Koster teaches a method, wherein the mass-modifying functionality is -XR, wherein X is selected from -0-, SCN and R is selected from alkyls, alkoxy and aryls and polyethylene glycols (Column 10, lines 1-36).

Koster teaches a method, wherein the mass-modifying functionality is thiol moiety (Column 3, line 47 and column 8, lines 10-17).

Koster teaches a method, wherein the alkyl moiety is generated by using iodoacetamide (Column 9, lines 16-27).

Koster teaches a method, further comprising the step of removing alkali cations by ion exchange comprising ammonium carbonate (Column 9, lines 11-16 and column 13, lines 1-4).

Koster teaches a method, further comprising the step of ligating the hybridized target nucleic acid to the probes (Figure 5).

Koster teaches a method, wherein the target nucleic acid is provided from a biological sample of a patient or from a recombinant source (Column 7, lines 19-40 and Column 11, lines 19-55).t

Art Unit:

Koster teaches a method, wherein the target nucleic acid and nucleic acid fragments and probes are between about 10 to about 1000 nucleotides in length (Examples 1-2).

Koster teaches a method, wherein each sequence of the nucleic acid fragments is homologous with at least a portion of the sequence of the target nucleic acid (Figures 1-8).

Koster teaches a method, wherein each sequence of the set of nucleic acid fragments is complementary with at least a portion of the sequence of the target nucleic acid (Example 1).

Koster teaches a method, wherein the fragments are provided by nuclease enzymatic digestion of the target nucleic acid (Column 4, lines 25-39).

Koster teaches a method, wherein the fragments are provided by physically cleaving the target nucleic acid (Examples 1-2).

Koster teaches a method, wherein the fragments are provided by enzymatic polymerization through polymerase chain reaction and the fragments comprise a nested set (Claims 9, 16, 20, and 43 and Examples 1-2).

Koster teaches a method, wherein the probes are single stranded (Examples 1-2 and Figures 1-6).

Koster inherently teaches a method, comprising the step of dephosphorylating the nucleic acid fragment by treatment with a phosphatase prior to hybridization (Column 8, lines 36-48).

Koster teaches a method, wherein the array comprises a collection of probes with sufficient sequence diversity in the variable regions to hybridize all of the target sequence with

Art Unit:

complete or nearly complete discrimination (Example 1 and Claim 1 and Figure 1 and Column 4, lines 11-14 and Column 9, lines 28-43 and Figures 2-3).

Koster teaches a method, wherein the variable region is about 4-20 nucleotides in length (Examples 1-2).

Koster teaches a method, wherein the array of nucleic acid probes are attached to a solid support selected from hybridization chips, beads, and combs (Figures 1-8 and Column 3, lines 60-67 and Examples 1-2 and Claim 30).

Koster teaches a method, wherein the probes are conjugated with biotin and the solid support is conjugated with streptavidin (Figure 4).

Koster teaches a method, wherein each probe is attached to the solid support by a photocleavable bond (Column 8, lines 18-60).

Koster teaches a method, wherein the cleavable bond is cleaved by an enzyme (Column 8, lines 36-48).

Koster teaches a method, wherein the chemical agent is reducing agent (Column 8, lines 36-40).

Koster teaches a method, wherein the electromagnetic radiation is visible radiation (Column 8, lines 18-34).

Koster teaches a method, comprising an oligonucleotide spacer between each probe and the solid support (Figures 1-8 and Column 7, line 65 to column 8, line 17).

Art Unit:

Koster teaches a method, wherein the solid support comprises a matrix that facilitates volatilization of nucleic acids for molecular weight determination (Column 2, lines 14-33).

Koster teaches an array of nucleic acid probes, comprising a collection of probes, wherein:

each probe comprises a single-stranded portion and a double-stranded portion (Figure 3);
each single-stranded portion comprises a variable sequence (Figure 3 and Examples 1-2);
the collection contains $4R$ probes, where R is the length of the variable region (Figures 1-3);

the collection of probes with sufficient sequence diversity in the variable regions to hybridize all of the target sequence with complete or nearly complete discrimination (Example 1 and Claim 1 and Figure 1 and Column 4, lines 11-14 and Column 9, lines 28-43 and Figures 2-3);

the array is attached to a solid support comprising a matrix that facilitates volatilization of nucleic acids for molecular weight determination (Column 2, lines 14-33).

Koster teaches a system, comprising:

a mass spectrometer, a computer (Column 2, lines 33-45), and the array as described above.

Art Unit:

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) a patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CAR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

7. Claims 1-55, 58-60, 63-70, 73-77, 86, and 88-128 are rejected under 35 U.S.C. 103 (a) over Koster (U.S. Patent 5,605,798) (February 25, 1997) in view of Weiss (U.S. Patent 6,025,193) (February 15, 2000).

Koster teaches claims 1-27, 29-55, 58-60, 63-70, 73-77, 86, and 88-128 as described above.

Koster does not teach the generation of thiol moiety by using Beucage reagent.

Weiss teaches the generation of thiol moiety by using Beucage reagent (Column 19, lines 10-26).

Art Unit:

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the generation of thiol moiety by using Beucage reagent of Weiss into the computerized method of sequencing of nucleic acids by mass spectrometry of Koster, since Weiss states, "By using the sulfurization reagent, each and every "O" group of the phosphodiester bond can be substituted with a sulfur group (Column 19, lines 19-21)." By employing scientific reasoning, an ordinary artisan would have combined and substituted the generation of thiol moiety by using Beucage reagent of Weiss into the computerized method of sequencing of nucleic acids by mass spectrometry of Koster in order to improve the analysis of nucleic acids. An ordinary practitioner would have been motivated to combine and substitute the generation of thiol moiety by using Beucage reagent of Weiss into the computerized method of sequencing of nucleic acids by mass spectrometry of Koster, in order to achieve the express advantages noted by Weiss, of a sulfurization reagent by which each and every "O" group of the phosphodiester bond can be substituted with a sulfur group.

8. Claims 1-27, 29-55, 58-60, 63-77, 86, and 88-128 are rejected under 35 U.S.C. 103 (a) over Koster (U.S. Patent 5,605,798) (February 25, 1997) in view of Sanghvi et al. (U.S. Patent 6,214,551) (April 10, 2001).

Koster teaches claims 1-27, 29-55, 58-60, 63-70, 73-77, 86, and 88-128 as described above.

Koster does not teach the selectively releasable bond is 4,4'-dimethoxytrityl or a derivative thereof including 3 or 4 [bis-(4-methoxyphenyl)]-methyl-benzoic acid.

Art Unit:

Sanghvi et al. teach the selectively releasable bond is 4,4'-dimethoxytrityl or a derivative thereof (Example 81, column 58, lines 3-32). Although Sanghvi et al do not teach the derivative 3 or 4 [bis-(4-methoxyphenyl)]-methyl-benzoic acid in particular but Sanghvi et al disclose equivalent compounds and derivatives used for the same purpose (Example 81).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the selectively releasable bond 4,4'-dimethoxytrityl or a derivative thereof and equivalent compounds and derivatives used for the same purpose of selectively releasing bonds of Sanghvi et al. into the computerized method of sequencing of nucleic acids by mass spectrometry of Koster, since Sanghvi et al. state, "This invention is also directed to methods for the selective binding of RNA for research and diagnostic purposes. Such selective, strong binding is accomplished by interacting such RNA or DNA with compositions of the invention which are resistant to degradative nucleases and which hybridize more strongly and with greater fidelity than known oligonucleotides or oligonucleotide analogs (Column 31, lines 19-25)." By employing scientific reasoning, an ordinary artisan would have combined and substituted the selectively releasable bond 4,4'-dimethoxytrityl or a derivative thereof and equivalent compounds and derivatives used for the same purpose of selectively releasing bonds of Sanghvi et al. into the computerized method of sequencing of nucleic acids by mass spectrometry of Koster in order to improve the analysis of nucleic acids. An ordinary practitioner would have been motivated to combine and substitute the selectively releasable bond 4,4'-dimethoxytrityl or a derivative thereof and equivalent compounds and derivatives used for

Art Unit:

the same purpose of selectively releasing bonds of Sanghvi et al. into the computerized method of sequencing of nucleic acids by mass spectrometry of Koster, in order to achieve the express advantages noted by Sanghvi et al., of an invention directed to methods for the selective binding of RNA for research and diagnostic purposes whereas such selective, strong binding is accomplished by interacting such RNA or DNA with compositions of the invention which are resistant to degradative nucleases and which hybridize more strongly and with greater fidelity than known oligonucleotides or oligonucleotide analogs.

Response to Amendment

9. In response to amendment, the finality of previous office action has been withdrawn and new 112 (second paragraph), 102(e), and 103(a) rejections have been included.

Response to Arguments

10. Applicant's arguments with respect to all pending claims have been considered but are moot in view of the new ground(s) of rejection.

Art Unit:

Conclusion

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D., whose telephone number is (703) 306-5818. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-7401. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Arun Chakrabarti,

Patent Examiner,

January 18, 2002



W. Gary Jones
Supervisory Patent Examiner
Technology Center 1600